X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/positive-xanamem-biomarker-trial-published-in-the-journal-of-alzheimers-disease-demonstrating-potential-xanamem-efficacy-in-patients-with-elevated-blood-ptau-302183198.html
https://www.prnewswire.com/news-releases/enrolment-completed-in-actinogens-xanacidd-phase-2a-cognition--depression-trial-302123276.html
https://www.prnewswire.com/news-releases/first-patient-treated-in-actinogens-xanamia-phase-2b-alzheimers-disease-trial-302116472.html
https://www.prnewswire.com/news-releases/actinogen-to-present-progress-on-phase-2-trials-at-the-bio-investor-forum-san-francisco-and-clinical-trials-on-alzheimers-disease-ctad-conference-boston-301956099.html
https://www.prnewswire.com/news-releases/actinogen-optimizes-xanamia-phase-2b-alzheimers-disease-trial-design-and-provides-general-business-update-301938890.html
https://www.prnewswire.com/news-releases/actinogen-to-present-progress-on-cognitive-impairment-in-depression-and-alzheimers-disease-phase-2-trials-at-the-bio-international-convention-301838636.html
https://www.prnewswire.com/news-releases/actinogen-presents-positive-phase-2a-xanamem-data-in-at-adpd-alzheimers-and-parkinsons-diseases-conference-301785380.html
Market Place
Share 
